SCHEMBL17859463

SCHEMBL17859463

Cc1nc2c(F)cc(C(=O)NCC(=O)O)cc2s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NR1H4 Q96RI1 1/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
CYP2C19 P33261 1/20 0.37
RAB9A P51151 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
NPC1 O15118 2/20 0.37
EGLN1 Q9GZT9 3/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HIF1A Q16665 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 2/20 0.36
CMA1 P23946 1/20 0.36
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17859468 0.81 NR1H4 (0.42) KMT2APOLBNR1H4GAALMNA
SCHEMBL17851275 0.81 NPC1 (0.51) KMT2ANR1H4GAALMNARAB9A
SCHEMBL17859465 0.78 NR1H4 (0.40) KMT2ANR1H4GAALMNARAB9A
SCHEMBL17859475 0.76 RAB9A (0.40) KMT2ATDP1NR1H4GAALMNA
SCHEMBL17851347 0.76 RAB9A (0.60) KMT2APOLBLMNARAB9ASMN1; SMN2
SCHEMBL17859474 0.76 POLB (0.53) POLBCYP2C19KDM4EALDH1A1
SCHEMBL20031251 0.75 NR1H4 (0.45) NR1H4RAB9ASMN1; SMN2NPC1MAPT
SCHEMBL18644571 0.72 RAB9A (0.35) KMT2ATDP1GAALMNARAB9A
SCHEMBL30616859 0.70 KDM4E (0.45) RAB9ASMN1; SMN2EGLN1MAPTKDM4E
SCHEMBL19705733 0.70 EGLN1 (0.43) KMT2APOLBTDP1RAB9AEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018059314-A1 AZABICYCLE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2018-04-05 WO disclosed
US-9751874-B2 Hydroxy containing FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2017-09-05 US disclosed
WO-2016096115-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-06-23 WO disclosed
US-20160176861-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176861-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H3, NR1H2 KMT2A 2491/4885POLB 3984/4885TDP1 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.